Images |
Sources |
Experiment + Assay |
Phenotypes |
Human Diseases |
|
Fig. 1 F G
Angerilli A et al. (2023)
|
Xla Wt + kmt5c MO + kmt5b MO (H1/H2 double KD)
NF28 (immunohistochemistry)
|
|
|
|
Fig. S4: A r2c2; Dr2 c2
Angerilli A et al. (2023)
|
Xla Wt + kmt5c MO + kmt5b MO (H1/H2 double KD)
NF28 (in situ hybridization)
|
|
|
|
Fig. 5 A: r2c2
Angerilli A et al. (2023)
|
Xtr Wt + kmt5b MO (suv4-20h1 NF4)
NF35/36 (in situ hybridization)
|
|
|
|
Fig. 5. A r4c2, B
Angerilli A et al. (2023)
|
Xtr Wt + kmt5b MO + kmt5c MO (H1/H2KD)
NF35/36 (in situ hybridization)
|
|
|
|
Fig. S5 r_2,c_2
Sempou E et al. (2022)
|
Xtr Wt + kcnh6 CRISPR (400pg)
NF17 (immunohistochemistry) tuba4b
|
|
|
|
Fig. 6 D
Bharathan NK and Dickinson AJG (2019)
|
Xla Wt + dsp MO
NF19-20 (immunohistochemistry)
|
|
skin disease
|
|
Fig. S 2 A, B
Sempou E et al. (2018)
|
Xtr Wt + fgfr4 CRISPR
NF17 (immunohistochemistry)
|
|
congenital heart disease
visceral heterotaxy
|
|
Fig. 4. H. J.
Zhou F et al. (2015)
|
Xla Wt + gmnc MO
NF29/30-29 and 30 (immunohistochemistry)
|
|
|
|
Fig. S4. B. C
Zhou F et al. (2015)
|
Xla Wt + Hsa.gmnc
NF29/30-29 and 30 (immunohistochemistry)
|
|
|
|
fig.4.a, b
Haremaki T et al. (2015)
|
Xla Wt + htt MO
NF29/30 (immunohistochemistry)
|
|
|